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Multiple rpoB
Mutants of
Mycobacterium
tuberculosis and
Second-order
Selection 
To the Editor: Rad and colleagues
recently described variation in some
genes involved in DNArepair (mutT2,
mutT4, ogt) in Mycobacterium tuber-
culosis strains of different genotypes
(1). This approach can also be used to
investigate developing rifampin
resistance in the context of emerging
mutator alleles. Resistance to
rifampin in M. tuberculosis strains is
usually caused by the point mutations
in the rpoB gene encoding the β-sub-
unit of the DNA-dependent RNA
polymerase, which is a target of the
drug. Although a single point muta-
tion is sufficient for developing
rifampin resistance, a number of arti-
cles (2,3) describe multiple rpoB
mutants for M. tuberculosis, i.e.,
rifampin-resistant strains harboring
mutations in different codons of rpoB.
Double, triple, and quadruple muta-
tions in M. tuberculosis clinical iso-
lates were reported in studies con-
ducted throughout the world (2,3).
Such emergence, albeit infrequent, of
M. tuberculosis rpoB multiple
mutants raises questions about their
biologic importance and underlying
mechanisms; answers to both remain
elusive.
I propose an explanation of these
observations in terms of second-order
selection of hypermutable (mutator)
alleles based on alterations in DNA
repair genes. Unlike that of other anti-
tuberculosis drugs, resistance to
rifampin is acquired in most M. tuber-
culosis isolates by altering a single
target molecule and offers the most
appropriate and straightforward
model to demonstrate possible hyper-
mutability in this species. In
mycobacteria, hypermutability was
demonstrated in vitro for M. smegma-
tis, a surrogate model for M. tubercu-
losis, as an increase in reversion
(mutant to wild-type) rate in rpoB526
or rpsL43 under counterselection by
streptomycin or rifampin, respectively
(4). A correlation between high muta-
tion rate and antimicrobial resistance
was reported for Pseudomonas aerug-
inosa isolates from lungs of cystic
fibrosis patients (5). The mutator P.
aeruginosa strains resulted from a
defective mismatch-repair system (5).
In  M. tuberculosis, mismatch-repair
genes (mutH, mutL, mutS, and recJ)
were not found in its genome (6).
However, the nucleotide pool in this
species is exceptionally clean because
of the presence of several copies of
the mutT gene (1,6); the MutT protein
removes oxidized guanines (8-Oxo-
dGTP), thus counteracting replication
or transcription errors. Consequently,
the MutHLS mismatch-repair system
simply may be not required in M.
tuberculosis (6). Therefore, hyper-
mutability in some strains of this
species resulting in multiple rpoB
mutants might develop under certain
special (in vivo) circumstances
through inactivation or down-regula-
tion of some mutT genes. Further, the
two most frequently described rpoB
mutations are 531TCG→TTG and
526CAC→TAC. Both are cytosine-
to-tymine transitions, which easily
occur by spontaneous cytosine deam-
ination to uracil. Indeed, M. tubercu-
losis is a G+C rich organism, there-
fore, it is naturally at high risk for
cytosine deamination. Furthermore,
pathogenic mycobacteria are at
increased risk for deamination
because of the production of reactive
oxygen and nitrogen intermediates
inside host macrophages. This deami-
nation process is normally counteract-
ed by uracil-N-glycosylase, the prod-
uct of the ung gene, and organisms
defective in the removal of uracil
from DNA have an increased sponta-
neous mutation rate and more
G:C→A:T base-pair transitions (7).
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Merchant et al., by using ung+ and
ung– Escherichia coli strains, demon-
strated that total nitric oxide expo-
sures in the µmol/L range can lead to
C→T mutations by a mechanism
probably involving cytosine deamina-
tion (8). On the other hand, in M.
smegmatis, the abrogation of the Ung
activity leads not only to increased
mutator phenotype but also to growth
inhibition by reactive nitrogen inter-
mediates (7). In summary, I speculate
that mutations in ung that do not com-
pletely impair function, but do
decrease synthesis of its product,
might tolerably increase the sponta-
neous C→T mutations, including
those in the respective positions in the
rpoB codons 531 and 526. This
assumption seems likely because both
of the aforementioned particular
mutations were described in sponta-
neous mutants of H37Rv obtained in
vitro and had a Darwinian fitness
slightly less than or equal to that of
the  rpoB wild-type-susceptible
parental strain (9). In contrast, the
translesion synthesis-based pathways
appear less likely to contribute to
emergence of such mutants, although
at least one of the translesion synthe-
sis genes (dinP) is present in the
genome of M. tuberculosis. In the E.
coli in vitro model, a translesion syn-
thesis enzyme (dinB encoded DNA
polymerase IV) activity clearly pro-
moted more important frameshift
mutations (single-base deletions) in
two thirds of the spontaneous mutants
(10).
From an evolutionary point of
view, the multiple rpoB mutations in
M. tuberculosis have been hypothe-
sized to arise as a compensatory
mechanism to ameliorate the fitness
costs of the original resistance muta-
tion by a secondary mutation (11).
The process of adaptation to the fit-
ness costs of chromosomally encoded
resistance has been studied in E. coli
and  Salmonella enterica serovar
Typhi for mutations that affect trans-
lation in the rpsL and fusR genes (11)
and for rpoB mutations in E. coli K12
strain (11). In the last instance, the
rpoB multiple mutants were selected
in vitro in a stepwise fashion, and one
double mutant, L511Q+D516G (also
described in M. tuberculosis strain
[3]), exhibited a relative fitness either
greater than or equal to either single
mutant or the wild type. Reynolds
(11) suggested that this allele is
favored not merely as a combination
of two low-level resistance mutations
but also because these mutations
together boost resistance and preserve
fitness. Whether the same is true for
other multiple mutant alleles in M.
tuberculosis rpoB remains to be seen.
Studying the costs of resistance of
multiple  rpoB mutations in a more
realistic environment of animal mod-
els of TB infection seems promising.
Igor Mokrousov*
*St. Petersburg Pasteur Institute, St.
Petersburg, Russia
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Human
Metapneumovirus
and Chronic
Obstructive
Pulmonary Disease 
To the Editor: We read with inter-
est an article, Human Meta-
pneumovirus Detection in Patients
with Severe Acute Respiratory
Syndrome, in your journal (1). In the
report, Chan et al., did not question
that SARS-CoV is the etiologic agent
of severe acute respiratory syndrome
(SARS); however, human metapneu-
movirus (HMPV) was found in 25
(52%) of 48 probable SARS cases that
were investigated, and SARS-CoV
was detected in 11 (22.9%) of them.
Another recent article reported
HMPV in five of six patients in whom
SARS was diagnosed in Canada (2);
four of the six were coinfected with
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